• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    2/29/24 12:35:24 PM ET
    $AKRO
    $ALNY
    $CI
    $CVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    NVAX PUT SWEEP BEARISH 01/16/26 $2.50 $80.7K 7.9K 4.8K
    CVS PUT SWEEP BULLISH 03/08/24 $75.00 $36.8K 2.8K 2.1K
    IOVA CALL SWEEP BEARISH 04/19/24 $20.00 $40.8K 3.4K 1.1K
    VKTX CALL TRADE BULLISH 03/01/24 $82.00 $26.0K 10 274
    MOH PUT TRADE BULLISH 03/15/24 $390.00 $26.1K 31 200
    LLY CALL TRADE NEUTRAL 04/19/24 $750.00 $32.2K 489 191
    ALNY CALL SWEEP BEARISH 09/20/24 $200.00 $78.4K 423 138
    AKRO CALL SWEEP BULLISH 03/15/24 $32.50 $43.2K 109 125
    CI CALL TRADE BULLISH 06/20/25 $420.00 $178.8K 0 120
    PRTA CALL TRADE BULLISH 06/21/24 $25.00 $33.0K 2 92

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For NVAX (NASDAQ:NVAX), we notice a put option sweep that happens to be bearish, expiring in 687 day(s) on January 16, 2026. This event was a transfer of 909 contract(s) at a $2.50 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $80.7K, with a price of $89.0 per contract. There were 7911 open contracts at this strike prior to today, and today 4853 contract(s) were bought and sold.

    • For CVS (NYSE:CVS), we notice a put option sweep that happens to be bullish, expiring in 8 day(s) on March 8, 2024. This event was a transfer of 206 contract(s) at a $75.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $36.8K, with a price of $179.0 per contract. There were 2859 open contracts at this strike prior to today, and today 2143 contract(s) were bought and sold.

    • For IOVA (NASDAQ:IOVA), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 19, 2024. This event was a transfer of 627 contract(s) at a $20.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $40.8K, with a price of $65.0 per contract. There were 3429 open contracts at this strike prior to today, and today 1106 contract(s) were bought and sold.

    • Regarding VKTX (NASDAQ:VKTX), we observe a call option trade with bullish sentiment. It expires in 1 day(s) on March 1, 2024. Parties traded 100 contract(s) at a $82.00 strike. The total cost received by the writing party (or parties) was $26.0K, with a price of $260.0 per contract. There were 10 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold.

    • For MOH (NYSE:MOH), we notice a put option trade that happens to be bullish, expiring in 15 day(s) on March 15, 2024. This event was a transfer of 45 contract(s) at a $390.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $580.0 per contract. There were 31 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a call option trade that happens to be neutral, expiring in 50 day(s) on April 19, 2024. This event was a transfer of 9 contract(s) at a $750.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $3580.0 per contract. There were 489 open contracts at this strike prior to today, and today 191 contract(s) were bought and sold.

    • For ALNY (NASDAQ:ALNY), we notice a call option sweep that happens to be bearish, expiring in 204 day(s) on September 20, 2024. This event was a transfer of 59 contract(s) at a $200.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $78.4K, with a price of $1330.0 per contract. There were 423 open contracts at this strike prior to today, and today 138 contract(s) were bought and sold.

    • For AKRO (NASDAQ:AKRO), we notice a call option sweep that happens to be bullish, expiring in 15 day(s) on March 15, 2024. This event was a transfer of 184 contract(s) at a $32.50 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $43.2K, with a price of $235.0 per contract. There were 109 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold.

    • For CI (NYSE:CI), we notice a call option trade that happens to be bullish, expiring in 477 day(s) on June 20, 2025. This event was a transfer of 120 contract(s) at a $420.00 strike. The total cost received by the writing party (or parties) was $178.8K, with a price of $1490.0 per contract. There were 0 open contracts at this strike prior to today, and today 120 contract(s) were bought and sold.

    • For PRTA (NASDAQ:PRTA), we notice a call option trade that happens to be bullish, expiring in 113 day(s) on June 21, 2024. This event was a transfer of 50 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $660.0 per contract. There were 2 open contracts at this strike prior to today, and today 92 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKRO
    $ALNY
    $CI
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Molina Healthcare Inc
    $MOH
    2/20/2026$141.00Overweight → Equal Weight
    Wells Fargo
    Alnylam Pharmaceuticals Inc.
    $ALNY
    1/28/2026$527.00Overweight
    Barclays
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Alnylam Pharmaceuticals Inc.
    $ALNY
    1/7/2026$500.00Outperform
    Oppenheimer
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    More analyst ratings

    $AKRO
    $ALNY
    $CI
    $CVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ALNY
    $CI
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Molina Healthcare downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Molina Healthcare from Overweight to Equal Weight and set a new price target of $141.00

    2/20/26 8:22:16 AM ET
    $MOH
    Medical Specialities
    Health Care

    Barclays resumed coverage on Alnylam Pharma with a new price target

    Barclays resumed coverage of Alnylam Pharma with a rating of Overweight and set a new price target of $527.00

    1/28/26 7:15:18 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ALNY
    $CI
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zoretic Richard C bought $100,128 worth of shares (800 units at $125.16) (SEC Form 4)

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    2/12/26 8:27:47 PM ET
    $MOH
    Medical Specialities
    Health Care

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    $AKRO
    $ALNY
    $CI
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AKRO
    $ALNY
    $CI
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AKRO
    $ALNY
    $CI
    $CVS
    SEC Filings

    View All

    Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 9:10 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to

    2/23/26 10:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

    Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and

    2/23/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on February 19, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance's common stock to two new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13,

    2/20/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief People Officer Dozier Eric gifted 481 shares, decreasing direct ownership by 3% to 14,455 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/19/26 4:18:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.16% to 2,966 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:27:23 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Luciano Juan R was granted 15 shares, increasing direct ownership by 0.09% to 16,772 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/18/26 4:26:10 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    2/19/26 4:07:15 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Molina Healthcare Inc

    SCHEDULE 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

    2/17/26 10:26:21 AM ET
    $MOH
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Molina Healthcare Inc

    SCHEDULE 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

    2/13/26 5:32:39 PM ET
    $MOH
    Medical Specialities
    Health Care

    $AKRO
    $ALNY
    $CI
    $CVS
    Financials

    Live finance-specific insights

    View All

    Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

    Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson's disease in 4Q 2025; primary completion exp

    2/19/26 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T

    2/12/26 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ALNY
    $CI
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ALNY
    $CI
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 3:59:41 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care